A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Trial Profile

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

At a glance

  • Drugs Atrasentan (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms SONAR
  • Sponsors AbbVie
  • Most Recent Events

    • 05 Aug 2017 Planned number of patients changed from 6200 to 5500.
    • 14 Apr 2017 Planned End Date changed from 1 Nov 2018 to 8 Apr 2020.
    • 05 Nov 2015 Interim results (n=4148) of population enriched design were presented at the 22nd World Congress of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top